SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 ------------------------------------------ FORM 10-Q (mark one) [ X ] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Quarter Ended March 29, 1997. [ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Commission File Number 1-9786 THERMO INSTRUMENT SYSTEMS INC. (Exact name of Registrant as specified in its charter) Delaware 04-2925809 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 1275 Hammerwood Avenue Sunnyvale, California 94089 (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (617) 622-1000 Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [ X ] No [ ] Indicate the number of shares outstanding of each of the issuer's classes of Common Stock, as of the latest practicable date. Class Outstanding at April 25, 1997 ---------------------------- ----------------------------- Common Stock, $.10 par value 97,214,545 PAGE PART I - FINANCIAL INFORMATION Item 1 - Financial Statements THERMO INSTRUMENT SYSTEMS INC. Consolidated Balance Sheet (Unaudited) Assets March 29, December 28, (In thousands) 1997 1996 ------------------------------------------------------------------------ Current Assets: Cash and cash equivalents $ 432,256 $ 522,688 Available-for-sale investments, at quoted market value (amortized cost of $7,470 and $7,430) 7,477 7,452 Accounts receivable, less allowances of $20,711 and $16,981 363,049 303,331 Unbilled contract costs and fees 7,720 6,043 Inventories: Raw materials and supplies 122,729 95,920 Work in process 59,478 47,518 Finished goods 103,020 70,245 Prepaid expenses 25,436 13,417 Prepaid income taxes 71,037 58,296 ---------- ---------- 1,192,202 1,124,910 ---------- ---------- Property, Plant, and Equipment, at Cost 306,107 250,976 Less: Accumulated depreciation and amortization 76,741 72,313 ---------- ---------- 229,366 178,663 ---------- ---------- Patents and Other Assets 31,691 32,454 ---------- ---------- Cost in Excess of Net Assets of Acquired Companies (Note 3) 930,862 588,373 ---------- ---------- $2,384,121 $1,924,400 ========== ========== 2PAGE THERMO INSTRUMENT SYSTEMS INC. Consolidated Balance Sheet (continued) (Unaudited) Liabilities and Shareholders' Investment March 29, December 28, (In thousands except share amounts) 1997 1996 ----------------------------------------------------------------------- Current Liabilities: Notes payable $ 189,598 $ 89,462 Accounts payable 102,002 83,161 Accrued payroll and employee benefits 57,597 51,728 Accrued income taxes 51,677 39,686 Accrued installation and warranty expenses 45,854 44,211 Accrued acquisition expenses (Note 3) 42,245 30,025 Deferred revenue 45,258 35,959 Other accrued expenses 137,021 101,646 Due to parent company 9,293 12,329 ---------- ---------- 680,545 488,207 ---------- ---------- Deferred Income Taxes 20,538 20,710 ---------- ---------- Other Deferred Items 27,944 29,805 ---------- ---------- Long-term Obligations: Senior convertible obligations (includes $140,000 due to parent company) 330,784 334,781 Subordinated convertible obligations 192,500 192,500 Other (includes $235,000 and $15,000 due to parent company; Note 3) 255,313 26,933 ---------- ---------- 778,597 554,214 ---------- ---------- Minority Interest 102,019 85,197 ---------- ---------- Shareholders' Investment: Common stock, $.10 par value, 250,000,000 shares authorized; 97,913,322 and 97,674,228 shares issued 9,791 9,767 Capital in excess of par value 323,682 319,464 Retained earnings 458,228 424,641 Treasury stock at cost, 706,230 and 750,055 shares (8,405) (8,679) Cumulative translation adjustment (8,822) 1,060 Net unrealized gain on available-for-sale investments 4 14 ---------- ---------- 774,478 746,267 ---------- ---------- $2,384,121 $1,924,400 ========== ========== The accompanying notes are an integral part of these consolidated financial statements. 3PAGE THERMO INSTRUMENT SYSTEMS INC. Consolidated Statement of Income (Unaudited) Three Months Ended ------------------------ March 29, March 30, (In thousands except per share amounts) 1997 1996 ------------------------------------------------------------------------ Revenues $329,120 $225,571 -------- -------- Costs and Operating Expenses: Cost of revenues 173,448 118,207 Selling, general, and administrative expenses 89,569 65,709 Research and development expenses 23,407 16,549 Write-off of acquired technology - 3,500 -------- -------- 286,424 203,965 -------- -------- Operating Income 42,696 21,606 Interest Income 7,224 5,111 Interest Expense (includes $1,559 and $1,537 to parent company) (8,460) (6,290) Gain on Issuance of Stock by Subsidiaries (Note 4) 12,035 24,257 -------- -------- Income Before Provision for Income Taxes and Minority Interest Expense 53,495 44,684 Provision for Income Taxes 17,770 10,073 Minority Interest Expense 2,138 568 -------- -------- Net Income $ 33,587 $ 34,043 ======== ======== Earnings per Share: Primary $ .35 $ .37 ======== ======== Fully diluted $ .32 $ .33 ======== ======== Weighted Average Shares: Primary 97,071 91,875 ======== ======== Fully diluted 111,442 107,269 ======== ======== The accompanying notes are an integral part of these consolidated financial statements. 4PAGE THERMO INSTRUMENT SYSTEMS INC. Consolidated Statement of Cash Flows (Unaudited) Three Months Ended ----------------------- March 29, March 30, (In thousands) 1997 1996 ----------------------------------------------------------------------- Operating Activities: Net income $ 33,587 $ 34,043 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and amortization 11,662 9,036 Provision for losses on accounts receivable 1,084 413 Gain on issuance of stock by subsidiaries (Note 4) (12,035) (24,257) Write-off of acquired technology - 3,500 Minority interest expense 2,138 568 Decrease in deferred income taxes - (40) Other noncash expenses 1,419 1,138 Changes in current accounts, excluding the effects of acquisitions: Accounts receivable (12,326) 8,814 Inventories (10,436) (6,998) Other current assets (7,745) 1,168 Accounts payable (404) (1,861) Other current liabilities (1,439) 5,012 Other (28) 198 --------- --------- Net cash provided by operating activities 5,477 30,734 --------- --------- Investing Activities: Acquisitions, net of cash acquired (Note 3) (336,935) (239,406) Purchases of property, plant, and equipment (3,989) (5,370) Other 601 1,527 --------- --------- Net cash used in investing activities (340,323) (243,249) --------- --------- Financing Activities: Net proceeds from issuance of Company and subsidiaries' common stock (Note 4) 25,219 42,010 Short-term borrowings from parent company - 89,012 Proceeds from issuance of short-term obligation to parent company - 30,000 Proceeds from issuance of long-term obligations to parent company (Note 3) 220,000 - Repayment of long-term obligations (253) (1,139) --------- --------- Net cash provided by financing activities $ 244,966 $ 159,883 --------- --------- 5PAGE THERMO INSTRUMENT SYSTEMS INC. Consolidated Statement of Cash Flows (continued) (Unaudited) Three Months Ended ----------------------- March 29, March 30, (In thousands) 1997 1996 ----------------------------------------------------------------------- Exchange Rate Effect on Cash $ (552) $ (128) --------- --------- Decrease in Cash and Cash Equivalents (90,432) (52,760) Cash and Cash Equivalents at Beginning of Period 522,688 395,233 --------- --------- Cash and Cash Equivalents at End of Period $ 432,256 $ 342,473 ========= ========= Noncash Activities: Fair value of assets of acquired companies $ 607,466 $ 494,240 Cash paid for acquired companies (383,247) (251,964) Cash to be paid for remaining outstanding shares of tender offer (21,102) - Issuance of subsidiary stock options for acquisition (2,080) - --------- --------- Liabilities assumed of acquired companies $ 201,037 $ 242,276 ========= ========= Conversions of convertible obligations $ 3,997 $ 14,356 ========= ========= The accompanying notes are an integral part of these consolidated financial statements. 6PAGE THERMO INSTRUMENT SYSTEMS INC. Notes to Consolidated Financial Statements 1. General The interim consolidated financial statements presented have been prepared by Thermo Instrument Systems Inc. (the Company) without audit and, in the opinion of management, reflect all adjustments of a normal recurring nature necessary for a fair statement of the financial position at March 29, 1997, the results of operations for the three-month periods ended March 29, 1997, and March 30, 1996, and the cash flows for the three-month periods ended March 29, 1997, and March 30, 1996. Interim results are not necessarily indicative of results for a full year. The consolidated balance sheet presented as of December 28, 1996, has been derived from the consolidated financial statements that have been audited by the Company's independent public accountants. The consolidated financial statements and notes are presented as permitted by Form 10-Q and do not contain certain information included in the annual financial statements and notes of the Company. The consolidated financial statements and notes included herein should be read in conjunction with the financial statements and notes included in the Company's Annual Report on Form 10-K for the fiscal year ended December 28, 1996, as amended, filed with the Securities and Exchange Commission. 2. Presentation Certain amounts in 1996 have been reclassified to the presentation in the 1997 financial statements. 3. Acquisitions In March 1997, the Company acquired 166,557,897 shares (or approximately 95%) of Life Sciences International PLC (Life Sciences), a London Stock Exchange-listed company, for 135 pence per share (approximately $2.15 per share, or an aggregate of approximately $362.7 million, including related expenses) in completion of the Company's offer to acquire all of the outstanding shares of Life Sciences. The Company expects to acquire the Life Sciences shares that remain outstanding for 135 pence per share pursuant to the compulsory acquisition rules applicable to United Kingdom companies. The accompanying balance sheet as of March 29, 1997, includes $21.1 million accrued for the purchase of the remaining Life Sciences shares outstanding, plus shares issuable upon exercise of outstanding stock options. Subsequent to the end of the quarter, the Company repaid approximately $75 million of Life Sciences' debt. Life Sciences manufactures laboratory science equipment, appliances, instruments, consumables, and reagents for the research, clinical, and industrial markets. To partially finance the acquisition of Life Sciences, the Company borrowed $210.0 million from Thermo Electron Corporation (Thermo Electron) pursuant to a promissory note due March 1999, and bearing interest at the Commercial Paper Composite Rate plus 25 basis points, set at the beginning of each quarter. 7PAGE THERMO INSTRUMENT SYSTEMS INC. 3. Acquisitions (continued) During the first quarter of 1997, the Company made several other acquisitions for approximately $20.5 million in cash, the issuance of subsidiary stock options valued at an aggregate $2.1 million, and a subsidiary's issuance of a $10.0 million promissory note to Thermo Electron, which is due March 1999, and bears interest at the 90-day Commercial Paper Composite Rate plus 25 basis points, set at the beginning of each quarter. The acquisitions completed in the first quarter of 1997 have been accounted for using the purchase method of accounting and their results have been included in the accompanying financial statements from their respective dates of acquisition. The cost of these acquisitions exceeded the estimated fair value of the acquired net assets by $349.5 million, which is being amortized over 40 years. Allocation of the purchase price for these acquisitions was based on estimates of the fair value of the net assets acquired and is subject to adjustment upon finalization of the purchase price allocation. Based on unaudited data, the following table presents selected financial information for the Company and Life Sciences on a pro forma basis, assuming the companies had been combined since the beginning of 1996. The effect of the acquisitions not included in the pro forma data was not material to the Company's results of operations. Three Months Ended -------------------------- March 29, March 30, (In thousands except per share amounts) 1997 1996 ------------------------------------------------------------------------ Revenues $381,892 $307,232 Net income 20,485 30,813 Earnings per share: Primary .21 .34 Fully diluted .20 .30 The pro forma results are not necessarily indicative of future operations or the actual results that would have occurred had the acquisition of Life Sciences been made at the beginning of 1996. During 1996, the Company had undertaken a restructuring of a substantial portion of the businesses comprising the Scientific Instruments Division of Fisons plc (Fisons), acquired in March 1996. During the first quarter of 1997, the Company expended $5.1 million for restructuring costs, primarily for severance and abandoned facility payments. In connection with finalizing its restructuring plans for the businesses acquired from Fisons, the Company recorded an additional $8.1 million of acquisition reserves in the first quarter of 1997, primarily for the abandonment of excess facilities, as well as severance. This amount was recorded as an increase in cost in excess of net assets of acquired companies. The remaining reserve for restructuring these businesses was $20.6 million at March 29, 1997, which primarily represents ongoing severance and abandoned facility payments. As of March 29, 1997, the Company has accrued $42.2 million in connection with 8PAGE THERMO INSTRUMENT SYSTEMS INC. 3. Acquisitions (continued) restructuring activities of all of its acquisitions, including the businesses acquired from Fisons. 4. Issuance of Stock by Subsidiary In March 1997, the Company's ThermoQuest Corporation (ThermoQuest) subsidiary sold 1,768,500 shares of its common stock at $15.00 per share for net proceeds of approximately $25 million, resulting in a gain of approximately $12 million. Following the sale, the Company owned 90% of ThermoQuest's outstanding common stock. Item 2 - Management's Discussion and Analysis of Financial Condition and Results of Operations Forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, are made throughout this Management's Discussion and Analysis of Financial Condition and Results of Operations. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "seeks," "estimates," and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause the results of the Company to differ materially from those indicated by such forward-looking statements, including those detailed under the caption "Forward-looking Statements" in Exhibit 13 to the Company's Annual Report on form 10-K for the fiscal year ended December 28, 1996, filed with the Securities and Exchange Commission. Results of Operations First Quarter 1997 Compared With First Quarter 1996 Revenues increased $103.5 million, or 46%, to $329.1 million in the first quarter of 1997 from $225.6 million in the first quarter of 1996 due to acquisitions, which included Life Sciences International PLC (Life Sciences) in March 1997 (Note 3) and a substantial portion of the businesses comprising the Scientific Instruments Division of Fisons plc (Fisons) in March 1996. Acquisitions added revenues of $110.9 million in the first quarter of 1997. The increase in revenues from acquisitions was offset in part by a decrease of $8.0 million in revenues due to the unfavorable effects of currency translation as a result of the strengthening of the U.S. dollar relative to foreign currencies in countries in which the Company operates. An increase in revenues from ThermoQuest Corporation's (ThermoQuest) existing mass spectrometry business as a result of the continued success of a new product introduced in the first quarter of 1996 was offset by a decrease in revenues at certain of the Company's other existing businesses, principally Thermo Optek Corporation (Thermo Optek). Revenues from Thermo Optek's existing businesses decreased due to the inclusion in 1996 of several large nonrecurring sales to the Chinese and Japanese governments and the elimination of certain unprofitable acquired product lines. 9PAGE THERMO INSTRUMENT SYSTEMS INC. First Quarter 1997 Compared With First Quarter 1996 (continued) International sales account for a significant portion of the Company's total revenues. Although the Company seeks to charge its customers in the same currency as its operating costs, the Company's financial performance and competitive position can be affected by currency exchange rate fluctuations. Where appropriate, the Company uses forward exchange contracts to reduce its exposure to currency fluctuations. The gross profit margin remained relatively unchanged at 47.3% in the first quarter of 1997, compared with 47.6% in the first quarter of 1996. An increase in ThermoQuest's gross profit margin, primarily due to the increase in sales of higher-margin mass spectrometry products, was more than offset by the inclusion of lower-margin revenues from acquired businesses, including Life Sciences, which recorded an adjustment to expense of $2.7 million relating to the revaluation of the finished goods inventories acquired by the Company. Selling, general, and administrative expenses as a percentage of revenues decreased to 27% in the first quarter of 1997 from 29% in the first quarter of 1996, primarily due to efforts at Thermo Optek to reduce selling and administrative costs at certain acquired businesses and the integration of products from businesses acquired from Fisons into Thermo Optek's existing distribution channels. Research and development expenses as a percentage of revenues remained relatively unchanged at 7.1% in 1997, compared with 7.3% in 1996. In the first quarter of 1996, the Company wrote off $3.5 million of acquired technology in connection with the acquisition of a significant portion of the businesses comprising the Scientific Instruments Division of Fisons. Interest income increased to $7.2 million in the first quarter of 1997 from $5.1 million in the first quarter of 1996, due to interest income earned on invested proceeds from the issuance of $172.5 million principal amount of 4 1/2% senior convertible debentures by the Company in October 1996 and, to a lesser extent, from the sale of common stock by ThermoQuest, Thermo BioAnalysis Corporation (Thermo BioAnalysis), and Metrika Systems Corporation (Metrika Systems) in 1996. The increase in interest income was offset in part by a reduction in cash as a result of acquisitions. Interest expense increased to $8.5 million in 1997 from $6.3 million in 1996, primarily due to the issuance of the 4 1/2% senior convertible debentures by the Company and, to a lesser extent, the inclusion of interest expense on debt assumed as part of the Fisons and Life Sciences acquisitions. Subsequent to the end of the quarter, the Company repaid approximately $75 million of Life Sciences' debt. The Company expects to repay the remaining $30 million of Life Sciences' debt in June 1997. The increases in interest expense were offset in part by the conversion of a portion of the Company's convertible obligations into common stock of the Company. Interest expense will increase as a result of an aggregate $220.0 million in promissory notes issued to Thermo Electron Corporation (Thermo Electron) in connection with acquisitions (Note 3). 10PAGE THERMO INSTRUMENT SYSTEMS INC. First Quarter 1997 Compared With First Quarter 1996 (continued) The Company has adopted a strategy of spinning out certain of its businesses into separate subsidiaries and having these subsidiaries sell a minority interest to outside investors. The Company believes that this strategy provides additional motivation and incentives for the management of the subsidiaries through the establishment of subsidiary-level stock option incentive programs, as well as capital to support the subsidiaries' growth. As a result of the sale of stock by subsidiaries, the Company recorded gains of approximately $12 million in the first quarter of 1997 and $24 million in the first quarter of 1996 (Note 4). The size and timing of these transactions are dependent on market and other conditions that are beyond the Company's control. Accordingly, there can be no assurance that the Company will be able to realize gains from such transactions in the future. The effective tax rate increased to 33% in the first quarter of 1997 from 23% in the first quarter of 1996, primarily due to a lower nontaxable gain on issuance of stock by subsidiaries in 1997. Excluding the impact of the gain on issuance of stock by subsidiaries in 1997 and 1996, the effective tax rates in both periods exceeded the statutory federal income tax rate due to nondeductible amortization of cost in excess of net assets of acquired companies, the inability to provide a tax benefit on losses incurred at certain foreign subsidiaries, the impact of state income taxes, and in 1996, the write-off of acquired technology in connection with the acquisition of the businesses from Fisons. Minority interest expense increased to $2.1 million in the first quarter of 1997 from $0.6 million in the first quarter of 1996, primarily due to the minority interest associated with the Company's newly public ThermoQuest, Thermo Optek, and Thermo BioAnalysis subsidiaries. Liquidity and Capital Resources Consolidated working capital was $511.7 million at March 29, 1997, compared with $636.7 million at December 28, 1996. Included in working capital are cash, cash equivalents, and available-for-sale investments of $439.7 million at March 29, 1997, and $530.1 million at December 28, 1996. Of the $439.7 million balance at March 29, 1997, $207.3 million was held by ThermoQuest, $61.5 million by Thermo Optek, $12.2 million by ThermoSpectra, $59.2 million by Thermo BioAnalysis, $17.4 million by Metrika Systems, and $82.1 million by the Company and its wholly owned subsidiaries. The Company's operating activities provided cash of $5.5 million in the first quarter of 1997. Accounts receivable increased $12.3 million primarily due to increased shipments by one of ThermoQuest's foreign subsidiaries in the first quarter of 1997, compared with the fourth quarter of 1996, and an increase in accounts receivable at Life Sciences from the date of its acquisition by the Company. Inventories increased $10.4 million primarily due to replenishing year-end levels, which had decreased by $17.2 million during the fourth quarter of 1996. At March 29, 1997, $104.6 million of the Company's cash and cash equivalents was held by its foreign subsidiaries. While this cash can be used outside of the United States, including for acquisitions, 11PAGE THERMO INSTRUMENT SYSTEMS INC. Liquidity and Capital Resources (continued) repatriation of this cash into the United States would be subject to foreign withholding taxes and could also be subject to a United States tax. The Company's investing activities used $340.3 million of cash in the first quarter of 1997. The Company expended $336.9 million for acquisitions (Note 3) and $4.0 million for the purchase of property, plant, and equipment. Subsequent to the end of the quarter, the Company repaid approximately $75 million of Life Sciences' debt. The Company expects to repay the remaining $30 million of Life Sciences' debt in June 1997. Such debt is included in current notes payable in the accompanying 1997 balance sheet. The Company's financing activities provided $245.0 million of cash in the first quarter of 1997. In March 1997, to partially finance acquisitions, the Company borrowed an aggregate $220.0 million from Thermo Electron pursuant to promissory notes due March 1999 (Note 3). In March 1997, ThermoQuest sold shares of its common stock for net proceeds of approximately $25 million (Note 4). In April 1997, Metrika Systems filed a registration statement under the Securities Act of 1933 with the Securities and Exchange Commission covering shares of common stock to be offered in its initial public offering. During the remainder of 1997, the Company plans to make expenditures of approximately $21 million for property, plant, and equipment. The Company believes that its existing resources are sufficient to meet the capital requirements of its existing operations for the foreseeable future. The Company has historically complemented internal development with acquisitions of businesses or technologies that extend the Company's presence in current markets or provide opportunities to enter and compete effectively in new markets. The Company will consider making acquisitions of such businesses or technologies that are consistent with its plans for strategic growth. The Company expects that it will finance these acquisitions through a combination of internal funds, additional debt or equity financing from the capital markets, or short-term borrowings from Thermo Electron, although there is no agreement with Thermo Electron to ensure that funds will be available on acceptable terms or at all. 12PAGE THERMO INSTRUMENT SYSTEMS INC. PART II - OTHER INFORMATION Item 6 - Exhibits and Reports on Form 8-K (a) Exhibits See Exhibit Index on the page immediately preceding exhibits. (b) Reports on Form 8-K On January 22, 1997, the Company filed a Current Report on Form 8-K pertaining to its tender offer for all of the outstanding shares of Life Sciences International PLC. On April 4, 1997, the Company filed a Current Report on Form 8-K pertaining to its acquisition of Life Sciences International PLC. 13PAGE THERMO INSTRUMENT SYSTEMS INC. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized as of the 6th day of May 1997. THERMO INSTRUMENT SYSTEMS INC. Paul F. Kelleher ---------------------------- Paul F. Kelleher Chief Accounting Officer John N. Hatsopoulos ---------------------------- John N. Hatsopoulos Vice President and Chief Financial Officer 14PAGE THERMO INSTRUMENT SYSTEMS INC. EXHIBIT INDEX Exhibit Number Description of Exhibit ------------------------------------------------------------------------ 10.1 $210,000,000 Promissory Note dated as of March 27, 1997, issued by the Company to Thermo Electron Corporation. 11 Statement re: Computation of Earnings per Share. 27 Financial Data Schedule.